Frequency Therapeutics, a regenerative medicine developer advancing MIT and Harvard research, has set the range for an initial public offering that will raise $107m if it floats at the high end.
Frequency Therapeutics, a US-based regenerative medicine developer based on research at Massachusetts Institute of Technology (MIT) and Harvard University, set the terms for its initial public offering yesterday.
The company plans to issue 6.7 million shares priced between $14 and $16, and will raise between $93.8m and approximately $107m if it floats at the bottom and top of its range respectively.
Founded in 2015, Frequency is developing small molecule treatments that are intended to fix the damage…
